Publicaciones en las que colabora con MARÍA CONSUELO DEL CAÑIZO FERNÁNDEZ-ROLDÁN (117)

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2017

  1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes

    PLoS ONE, Vol. 11, Núm. 10

  2. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow

    Stem Cell Research and Therapy, Vol. 6, Núm. 1

  2. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  3. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

    Leukemia

  2. Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by BCR-ABL1 fusion gene

    American Journal of Hematology, Vol. 89, Núm. 3, pp. 288-294

  3. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

  4. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia

    Clinical Cancer Research, Vol. 20, Núm. 15, pp. 4014-4025

  5. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

  6. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

  7. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585

  8. Transcriptomic portrait of human Mesenchymal Stromal/Stem cells isolated from bone marrow and placenta

    BMC Genomics, Vol. 15, Núm. 1

  9. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

  2. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

    Annals of Hematology, Vol. 92, Núm. 11, pp. 1543-1552

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

  2. Bone marrow transplantation extends its scope

    Advances in Experimental Medicine and Biology, Vol. 741, pp. 121-134